Institute of Pathology

Sinonasal Undifferentiated Carcinoma (SNUC): From an Entity to Morphologic Pattern and Back Again-A Historical Perspective (2020) Agaimy A, Franchi A, Lund VJ, Skalova A, Bishop JA, Triantafyllou A, Andreasen S, et al. Journal article, Review article The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients (2020) Alman B, Attia S, Baumgarten C, Benson C, Blay JY, Bonvalot S, Breuing J, et al. Journal article, Review article Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view (2020) Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R Journal article, Editorial Discrimination analysis of breast calcifications using x-ray dark-field radiography (2020) Rauch T, Rieger J, Pelzer G, Horn F, Erber R, Wunderle M, Emons J, et al. Journal article Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data (2020) Kim WY, Rose T, Roghmann F, Eckstein M, Jarczyk J, Zengerling F, Sikic D, et al. Conference contribution Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy (2020) Gupta S, Sonpavde G, Weight C, McGregor BA, Gupta S, Maughan BL, Wei X, et al. Conference contribution Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Roghmann F, Reike M, Wirtz R, Kriegmair M, Erben P, Tully K, Weyerer V, et al. Conference contribution Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Reike M, Juette H, Wirtz R, Erben P, Tully K, Eckstein M, Weyerer V, et al. Conference contribution Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas (2020) Bertz S, Enßer A, Stöhr R, Eckstein M, Apel H, Mayr D, Büttner-Herold M, et al. Journal article A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast) (2020) Ahrens M, Escudier B, Boleti E, Grimm MO, Goupir MG, Barthelemy P, Gravis G, et al. Conference contribution